KAPE-TECHNOLOGIES
1.8.2024 14:12:36 CEST | Business Wire | Press release
Kape Technologies today announced the appointment of Ankit Khemka as Chief Marketing Officer (CMO), strengthening the group’s senior leadership team and bolstering the company’s commitment to building a safer, freer internet with its industry-leading privacy and security technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240801380656/en/
Ankit Khemka (Photo: Business Wire)
Khemka is a seasoned professional with a diverse background in Brand Building, Growth Marketing and strategic business development. Most recently, Khemka served as Global General Manager and Head of Marketing at Revolut. Prior to this, he worked at HelloFresh and Rocket Internet Group, building and scaling businesses across the US, India, Europe, and Latin America.
Khemka will leverage his global experience in fast-growing companies to accelerate the growth of Kape’s privacy products, including its flagship privacy brand, ExpressVPN. In his new position, he will lead marketing activities, reinforcing the company’s strong customer-centric culture and driving initiatives to maximize growth opportunities.
"I am delighted to appoint Ankit to propel the next chapter of growth and innovation for Kape Technologies and its brands. The leadership team and I share a strong vision for the future of Kape. I am confident that Ankit’s marketing leadership and vision will be invaluable to our team as we continue to grow and innovate,” said Charles Butler, CEO, Kape Technologies. “Together we remain laser-focused on our mission to establish Kape as the world’s leading privacy-first digital security provider, empowering customers to take control of their privacy and security.”
Ankit Khemka, CMO, Kape Technologies said, “Kape Technologies’ flagship brand, ExpressVPN, has been at the forefront of the VPN industry for over a decade, thanks to its dedication to technical excellence, innovation, and customer-centricity. I am excited to build upon this solid foundation and unlock the immense potential for further growth. With our shared vision and the combined strength of our team, I am confident that we will take the company to new heights, setting the standard for the privacy and security industry.”
About Kape Technologies
Kape Technologies is a leading privacy-first digital security software provider to consumers. Through its range of privacy and security products, Kape focuses on protecting consumers and their personal data as they go about their daily digital lives.
With over 7 million paying subscribers, Kape has a proven track record of growth, underpinned by a strong business model and expert digital marketing. Kape's highly scalable SaaS-based operating structure is geared toward capitalizing on the vast global consumer digital privacy market.
About ExpressVPN
Since 2009, ExpressVPN has empowered millions of users to take control of their internet experience. The company’s award-winning consumer VPN service is backed by its open-source VPN protocol Lightway, delivering user privacy in just a few clicks. ExpressVPN’s Keys password manager and Aircove router make digital privacy and security easy and accessible for all. ExpressVPN’s products have been extensively vetted by third-party experts, including PwC, Cure53, KPMG, and others.
ExpressVPN has been part of Kape Technologies since 2021. To learn more about ExpressVPN’s industry-leading privacy and security solutions, visit www.expressvpn.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801380656/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom